Viral URI

Saturday, May 02, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. Clinical Evaluation of NESOSPRAY HE-C, a Nasal Spray, for Rhinopharyngitis and Rhinosinusitis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Medicina (Kaunas, Lithuania) (2025) - RCT

Key Findings

NESOSPRAY HE-C reduced total rhinosinusitis symptom severity vs placebo from day 3 onward, with sustained superiority through day 8 (p < 0.0001).
Rhinorrhea and nasal congestion improved within 2 hours vs placebo (p = 0.0089), while cough, poor sleep, and facial pain also improved by day 3.
Treatment was well tolerated, with no increase in serious adverse events vs placebo and no allergic reactions reported across children, pregnant women, and adults.

📋 Practice Implication: For uncomplicated viral URI with prominent nasal symptoms, a non-systemic barrier-forming nasal spray is a reasonable symptomatic option when patients want relief without oral medication exposure.

2. High-flow nasal oxygen versus conventional oxygen therapy in patients with hypoxemic COVID-19 pneumonia: A randomized controlled trials based meta-analysis.

Respiratory medicine (2026) - Meta-Analysis

Key Findings

High-flow nasal oxygen lowered total intubation risk vs conventional oxygen therapy (RR 0.86, 95% CI 0.78 to 0.95; p = 0.003).
Time to oxygen de-escalation was shorter by 3.53 days, with improved post-therapy respiratory rate, PaCO2, and SpO2/FiO2 metrics (all p <= 0.003).
Mortality rates were similar vs conventional oxygen therapy despite better respiratory support outcomes.

📋 Practice Implication: When a viral respiratory illness progresses to hypoxemic pneumonia, high-flow nasal oxygen should be considered early to reduce intubation exposure even if a mortality benefit is not established.

3. A Systematic Review and Meta-Analysis of Immunogenicity and Safety of the Influenza Vaccine in COPD Patients, and Its Relevance with Real-World Effectiveness.

International journal of chronic obstructive pulmonary disease (2026) - Meta-Analysis

Key Findings

Intradermal vaccination produced pooled seroconversion rates of 68.6% for A/H1N1 and 65.8% for A/H3N2 in COPD cohorts.
Geometric mean titers were higher with intradermal vs intramuscular vaccination, especially for A/H1N1 (8.38 vs 7.98) and A/H3N2 (7.97 vs 7.44).
Local reactions increased with intradermal vaccination, including erythema in 31.5% and swelling in 28.7%, while systemic fever remained below 5%.

📋 Practice Implication: In COPD patients, annual influenza vaccination remains a high-yield prevention strategy, and route-specific reactogenicity can be discussed without overstating short-term systemic harms.

4. Safety and efficacy of anti-IL-5 monoclonal antibodies as second-line therapy for chronic rhinosinusitis with nasal polyps: a meta-analysis.

Frontiers in immunology (2026) - Meta-Analysis

Key Findings

Anti-IL-5 therapy reduced nasal polyp score vs placebo (WMD -0.58, 95% CI -0.70 to -0.46; p < 0.00001) and improved SNOT-22 score by 9.57 points.
Nasal blockage, loss of smell, Lund-Mackay score, and visual analog symptom scores all improved vs placebo, with fewer patients needing systemic corticosteroids (RR 0.73, 95% CI 0.62 to 0.86).
First-time nasal polyp surgery trended lower vs placebo (RR 0.64, 95% CI 0.41 to 1.00), while overall safety remained acceptable.

📋 Practice Implication: Patients who appear to have recurrent 'viral sinus' complaints but actually have refractory polyp-driven disease may benefit more from ENT/allergy escalation than repeated symptomatic treatment alone.

5. Vitamin D for preventing acute respiratory infections in children up to five years of age.

The Cochrane database of systematic reviews (2026) - Meta-Analysis

Key Findings

Vitamin D supplementation slightly reduced the proportion of children with ARI-related healthcare visits vs placebo (RR 0.95, 95% CI 0.91 to 1.00; p = 0.03).
Higher-dose vs lower-dose vitamin D did not reduce the proportion of children making ARI-related visits (RR 0.94, 95% CI 0.81 to 1.10).
Hypercalcemia risk showed little to no increase vs placebo, with no reported cases among pregnant women in placebo comparisons and no clear excess risk in children.

📋 Practice Implication: For children under five, standard-dose vitamin D is best framed as a low-risk preventive adjunct with small absolute benefit rather than a high-impact URI prevention measure.

💡 Summary

Recent viral URI evidence emphasizes modest but actionable gains from prevention and symptom-directed care, with vitamin D and influenza vaccination supporting risk reduction in selected populations and a film-forming nasal spray improving acute rhinopharyngitis symptoms. For escalation pathways, high-flow nasal oxygen improved intubation-related outcomes in viral pneumonia, while biologic therapy data for chronic rhinosinusitis with nasal polyps support referral when upper-airway inflammation becomes persistent rather than self-limited.